Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?

The basal insulin market is so lousy with pricing pressures—and the products are so costly to make—that Merck has canceled its deal with Samsung Bioepis for a Lantus biosimilar. But even with Merck out of the game, it's unclear whether Mylan and partner Biocon can deal with those challenges.